中华结直肠疾病电子杂志
中華結直腸疾病電子雜誌
중화결직장질병전자잡지
Chinese Journal of Colorectal Diseases
2014年
3期
22-25
,共4页
肿瘤,继发原发性%观察%药理作用分子作用机制%分子靶向治疗
腫瘤,繼髮原髮性%觀察%藥理作用分子作用機製%分子靶嚮治療
종류,계발원발성%관찰%약리작용분자작용궤제%분자파향치료
Neoplasms,second primary%Observation%Molecular mechanisms of pharmacological action%Cetuximab therapy
目的：探讨分子靶向药重组人源化单克隆抗体西妥昔单抗联合化疗治疗老年胃、肠癌患者的临床疗效及其产生抗癌作用的机制。方法将我院收治的82例胃、肠癌老年患者随机分为观察组和对照组，每组均为41例。对照组采用以氟尿嘧啶为基础的常规FOLFOX4化疗方案，观察组在此基础上加用重组人源化抗VEGF单克隆抗体西妥昔单抗，观察两组患者临床疗效及不良反应发生情况。结果观察组临床治疗有效率为60．9％，临床症状控制率为90．2％，癌细胞凋亡率为27．3±2．83％，对照组临床治疗有效率为34．1％，临床症状控制率为68．2％，癌细胞凋亡率为25．4±2．67％，两组患者以上指标差异有统计学意义（P＜0．05）；两组间的毒副反应发生率差异无统计学意义（P＞0．05）。结论分子靶向药物重组人源化单克隆抗体西妥昔单抗用于治疗恶性肿瘤能取得显著临床疗效和提高患者生活质量，而毒副反应发生率无显著变化。
目的：探討分子靶嚮藥重組人源化單剋隆抗體西妥昔單抗聯閤化療治療老年胃、腸癌患者的臨床療效及其產生抗癌作用的機製。方法將我院收治的82例胃、腸癌老年患者隨機分為觀察組和對照組，每組均為41例。對照組採用以氟尿嘧啶為基礎的常規FOLFOX4化療方案，觀察組在此基礎上加用重組人源化抗VEGF單剋隆抗體西妥昔單抗，觀察兩組患者臨床療效及不良反應髮生情況。結果觀察組臨床治療有效率為60．9％，臨床癥狀控製率為90．2％，癌細胞凋亡率為27．3±2．83％，對照組臨床治療有效率為34．1％，臨床癥狀控製率為68．2％，癌細胞凋亡率為25．4±2．67％，兩組患者以上指標差異有統計學意義（P＜0．05）；兩組間的毒副反應髮生率差異無統計學意義（P＞0．05）。結論分子靶嚮藥物重組人源化單剋隆抗體西妥昔單抗用于治療噁性腫瘤能取得顯著臨床療效和提高患者生活質量，而毒副反應髮生率無顯著變化。
목적：탐토분자파향약중조인원화단극륭항체서타석단항연합화료치료노년위、장암환자적림상료효급기산생항암작용적궤제。방법장아원수치적82례위、장암노년환자수궤분위관찰조화대조조，매조균위41례。대조조채용이불뇨밀정위기출적상규FOLFOX4화료방안，관찰조재차기출상가용중조인원화항VEGF단극륭항체서타석단항，관찰량조환자림상료효급불량반응발생정황。결과관찰조림상치료유효솔위60．9％，림상증상공제솔위90．2％，암세포조망솔위27．3±2．83％，대조조림상치료유효솔위34．1％，림상증상공제솔위68．2％，암세포조망솔위25．4±2．67％，량조환자이상지표차이유통계학의의（P＜0．05）；량조간적독부반응발생솔차이무통계학의의（P＞0．05）。결론분자파향약물중조인원화단극륭항체서타석단항용우치료악성종류능취득현저림상료효화제고환자생활질량，이독부반응발생솔무현저변화。
Objective To explore the clinical efficacy of avastin combined with chemotherapy in the treatment of gastrointestinal cancer.Methods 82 elderly patients with gastrointestinal cancer were randomly divided into observation group and control group .There were 41 cases in each group .The control group was given conventional FOLFOX 4 chemotherapy ,while the observation group was given the monoclonal antibody Avastin in the basis of the FOLFOX4 chemotherapy.The clinical efficacy and the incidence of adverse reactions were observed.Results In the observation group,the clinical efficiency was 58.1%,the clinical symptom control rate was 88.4%,the cancer cell apoptosis rate was 27.3 ±2.83%.While in the control group,the clinical efficiency was 58.1%, the clinical symptom control rate was 88.4%, the cancer cell apoptosis rate was 27.3 ±2.83%.There were significant differences between the two groups in the above indicators(P<0.05).However,the incidence of toxic reaction did not show significant difference between the two groups(P>0.05).Conclusion Cetuximab can significantly improve the clinical efficacy in the treatment of gastrointestinal malignant tumors .
